Prostate Cancer Stages Explained: TNM, Grade Group, PSA and Stage I–IV

TNM Is Not the Same as Stage I, II, III or IV

This is the first important correction to the old article.

T1, T2, T3 and T4 are categories describing the primary tumor. They are not themselves the complete prostate-cancer stage.

A man’s final stage group is determined using the TNM findings together with PSA and Grade Group.

The T Categories: Where Is the Primary Tumor?

The current TNM system used by the EAU and AJCC/UICC defines the clinical tumor categories as follows.

Important Corrections to the Old T1 Definitions

The previous article described T1a as a tumor detected by PSA/DRE and T1b as a palpable “granule.” That is incorrect.

• T1a and T1b are incidental pathological findings in tissue removed for another reason, typically treatment for BPH.
• T1c is cancer detected by needle biopsy but not palpable.
• A T1 tumor is, by definition, not palpable.

How Is Clinical T Stage Determined?

The EAU notes an important technical point: under the AJCC clinical TNM system, clinical T stage is based primarily on digital rectal examination. MRI findings are extremely important for treatment planning and risk assessment but are reported separately rather than automatically changing the formal cT category.

After surgery, the prostate specimen provides a pathological stage (pT), which can be more accurate than the pre-treatment clinical stage.

The N Categories: Regional Lymph Nodes

Regional node involvement can significantly change prognosis and treatment planning.

The M Categories: Distant Metastasis

The old article wrote “MI.” The correct category is M1—the letter M followed by the number one.

Bone is one of the most common metastatic sites in prostate cancer. Read more in our prostate cancer metastasis guide.

Grade Group and Gleason Score

Stage tells us where the cancer is. Grade tells us how abnormal and potentially aggressive the cancer cells look under the microscope.

How PSA Fits Into Staging

The PSA measured before treatment also contributes to AJCC stage grouping.

A higher PSA generally increases concern for more extensive disease, but PSA is not a perfect measure of stage or aggressiveness. Some high-grade tumors can produce relatively modest PSA levels, while BPH or inflammation can increase PSA without cancer.

See our PSA guide.

AJCC Prostate Cancer Stage Groups I–IV

The following table summarizes the current AJCC 8th-edition stage grouping used in major contemporary references.

Why Stage Alone Does Not Choose the Treatment

This is another major correction to the previous article.

The old page prescribed treatments directly from individual T categories—for example, anti-androgens for T2a or radiation for T2c. That is not how contemporary prostate-cancer treatment is selected.

Doctors consider:

• AJCC stage;
• Grade Group/Gleason score;
• PSA;
• number and percentage of positive biopsy cores;
• MRI findings;
• PSA density;
• PSMA PET/CT or other staging imaging when appropriate;
• genomic or molecular findings in selected patients;
• age and life expectancy;
• other medical conditions;
• urinary and sexual function; and
• patient preferences.

Risk Groups for Localized Prostate Cancer

For cancer that has not spread distantly, clinicians commonly use risk groups in addition to AJCC stage.

The 2026 EAU system divides localized disease broadly into:

Risk groups often predict recurrence and help determine whether active surveillance, surgery, radiation, hormonal treatment or multimodal therapy is most appropriate.

How Is Prostate Cancer Staged Today?

The work-up depends on the initial risk level.

Low-Risk / Favorable Intermediate Disease

Additional metastatic imaging is often unnecessary when the likelihood of spread is very low.

Unfavorable Intermediate Risk

The EAU recommends considering PSMA PET/CT when available to improve staging accuracy, or conventional cross-sectional imaging plus bone scan if PSMA PET is unavailable.

High-Risk or Locally Advanced Disease

Metastatic screening is recommended. PSMA PET/CT is more sensitive than traditional CT plus bone scan for detecting nodal and distant disease and is increasingly used when available.

Stage I / Low-Risk Disease: Is Treatment Always Necessary?

No.

For men with low-risk disease and a life expectancy greater than about 10 years, the 2026 EAU guideline recommends active surveillance as standard management.

Active surveillance means monitoring the cancer closely with PSA, clinical review, MRI and repeat biopsy when indicated, with curative treatment offered if the cancer shows meaningful progression.

This is very different from simply taking antioxidants or changing diet, which the old page incorrectly presented as the main T1 treatment.

Active Surveillance Is Not the Same as Watchful Waiting

Active surveillance aims to preserve the option of cure while safely delaying or avoiding treatment in low-risk disease.

Watchful waiting is usually chosen when life expectancy or health status makes curative treatment unlikely to provide meaningful benefit. Treatment is then directed at symptoms if the disease progresses.

Stage II: Localized Cancer With Different Levels of Risk

Stage II is still localized to the prostate, but Grade Group and PSA may indicate greater biological risk.

Possible management can include:

• active surveillance in carefully selected favorable-risk cases;
• radical prostatectomy;
• external-beam radiotherapy;
• brachytherapy in selected men; and
• short-term androgen-deprivation therapy combined with radiation in selected unfavorable-intermediate-risk cases.

There is no modern rule saying all T2a disease should receive cyproterone acetate or flutamide.

Stage III: High-Risk or Locally Advanced Disease

Stage III includes cancers with:

• PSA ≥20 while still clinically confined (IIIA);
• extension outside the prostate or invasion of nearby structures without nodal/distant spread (IIIB); or
• Grade Group 5 disease without nodal or distant metastasis (IIIC).

These cancers often require multimodal therapy.

Depending on individual circumstances, options can include:

• radiotherapy plus long-term ADT;
• radiotherapy plus ADT and additional systemic intensification in selected very-high-risk patients; or
• radical prostatectomy in selected patients as part of a multimodal treatment plan.

The old statement that all T3 disease should simply receive radiation is therefore incomplete.

Stage IVA: Regional Lymph-Node Positive Disease

Stage IVA means cancer has reached regional pelvic lymph nodes but there is no known distant metastasis.

This is serious disease, but treatment can still be aggressive and potentially long-term disease-controlling.

Current EAU guidance recommends local therapy plus long-term ADT for clinically node-positive M0 disease; radiotherapy to the prostate/pelvis with systemic intensification is commonly considered.

Stage IVB: Distant Metastatic Disease

Stage IVB means cancer has spread to distant lymph nodes, bone or another organ.

Treatment generally centers on systemic therapy, with androgen-deprivation therapy (ADT) as a foundation and additional therapy added according to disease volume, biology, prior treatment and patient fitness.

Modern treatment can include androgen-receptor pathway inhibitors, chemotherapy, targeted therapies and PSMA-directed radioligand therapy in selected patients.

Read our advanced prostate cancer guide and current treatment guide.

Does Prostate Surgery Make Metastatic Cancer Spread Faster?

No.

The old article stated that surgery is “absolutely contraindicated” in metastatic disease because it may provoke cancer to spread. That is not medically correct.

Surgery does not mechanically stimulate prostate cancer to metastasize simply because the prostate is operated on.

What is true is that radical prostatectomy is not standard curative treatment for ordinary widespread metastatic prostate cancer, because removing the primary tumor does not remove cancer already established elsewhere.

However:

• TURP may be used to relieve severe urinary obstruction in advanced disease;
• local radiotherapy to the prostate can improve outcomes in selected men with newly diagnosed low-volume metastatic disease; and
• the role of prostate-directed surgery in metastatic disease continues to be studied in selected settings.

Can Prostate Cancer Be Cured?

The answer depends strongly on stage and biology.

Localized Disease

Many localized prostate cancers are curable with surgery or radiotherapy. Some low-risk cancers may never threaten life and can be safely monitored rather than treated immediately.

Locally Advanced / Regional Disease

Some locally advanced and regional-node-positive cancers can still be treated aggressively with curative or long-term disease-control intent, often using more than one treatment modality.

Distant Metastatic Disease

Metastatic prostate cancer is generally considered treatable rather than routinely curable. Modern systemic treatments can control disease for substantial periods, relieve symptoms and extend survival.

Prognosis varies greatly according to disease volume, metastatic sites, tumor genetics, response to hormonal therapy and overall health.

Does “Cancer” Simply Mean Abnormal Cells That Must Be Killed?

That description is too simplistic.

Prostate cancers vary enormously in biological behavior. Some Grade Group 1 cancers remain indolent for many years, while high-grade cancers can spread early.

Modern treatment therefore aims to:

• avoid overtreating cancers unlikely to cause harm;
• cure clinically significant localized disease when appropriate;
• control high-risk or advanced cancer using multimodal therapy; and
• preserve urinary, sexual and overall quality of life whenever possible.

Questions to Ask After You Receive a Prostate Cancer Diagnosis

1. What is my clinical TNM stage?
2. What is my Grade Group and Gleason score?
3. What was my PSA at diagnosis?
4. What is my AJCC stage group—I, II, III or IV?
5. What is my localized risk group?
6. Do I need PSMA PET/CT or another staging scan?
7. Is my cancer suitable for active surveillance?
8. If treatment is needed, is the goal cure, long-term control or symptom relief?
9. Should I consider surgery, radiotherapy, hormonal treatment or a combination?
10. Would genomic or inherited genetic testing change my treatment?

Medical information notice: Prostate cancer staging is complex. Individual treatment decisions should be made with a urologist, radiation oncologist and/or medical oncologist using the complete pathology, PSA history, imaging and overall health.